Search Within

Matthew G Fury

Formats
  1. Journal Article (57)
  2. Meeting Abstract (42)
  3. Book Section (2)
  4. Book Whole (1)
Groups
  1. Department of Medicine (93)
  2. Solid Tumor Oncology Division (93)
  3. Head and Neck Service (81)
  4. Radiology, Department of (53)
  5. Surgery (46)
  6. Radiation Oncology, Department of (41)

More Groups

People
  1. David Pfister (69)
  2. Eric Sherman (52)
  3. Nancy Lee (41)
  4. Sofia Haque (29)
  5. Alan Ho (26)
  6. Nora Katabi (20)

More People

Years
  1. 2022 (1)
  2. 2020 (1)
  3. 2019 (2)
  4. 2018 (1)
  5. 2017 (5)
  6. 2016 (3)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. International Journal of Radiation Oncology, Biology, Physics (19)
  3. Cancer Chemotherapy and Pharmacology (6)
  4. Cancer (5)
  5. Annals of Oncology (3)
  6. Head & Neck (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (34)
  2. Elsevier Inc. (29)
  3. Springer (10)
  4. Wiley Blackwell (6)
  5. Harborside Press (3)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (102)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers
    Journal Article

    Chaft, J. E.; Rusch, V.; Ginsberg, M. S.; Paik, P. K.; Finley, D. J.; Kris, M. G.; Price, K. A. R.; Azzoli, C. G.; Fury, M. G.; Riely, G. J.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma
    Journal Article

    Sherman, E. J.; Su, Y. B.; Lyall, A.; Schoder, H.; Fury, M. G.; Ghossein, R. A.; Haque, S.; Lisa, D.; Shaha, A. R.; Tuttle, R. M.; more...
    Thyroid (2013)

    Fulltext@MSK | Save
  • A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    Journal Article

    Fury, M. G.; Sherman, E.; Ho, A. L.; Xiao, H.; Tsai, F.; Nwankwo, O.; Sima, C.; Heguy, A.; Katabi, N.; Haque, S.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • Should cetuximab replace cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?
    Journal Article

    Riaz, N.; Sherman, E. J.; Fury, M.; Lee, N.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Fury, M. G.; Baxi, S. S.; Haque, S.; Korte, S. H.; Smith-Marrone, S.; Xiao, H.; Ghossein, R. A.; Fagin, J. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Efficacy of concurrent cetuximab (C225) versus 5-fluorouracil/carboplatin (5FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC)
    Meeting Abstract

    Shapiro, L. Q.; Sherman, E. J.; Koutcher, L.; Setton, J.; Zhang, Z.; Shi, W.; Rao, S. S.; Fury, M. G.; Wolden, S. L.; Kraus, D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib
    Meeting Abstract

    Ho, A. L.; Leboeuf, R.; Grewal, R. K.; Sherman, E. J.; Deandreis, D.; Pentlow, K. S.; Tuttle, R. M.; Fury, M. G.; Ricarte-Filho, J. C. M.; Pfister, D. G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of everolimus (E) plus weekly cisplatin (CDDP) plus intensity-modulated radiation therapy (IMRT) in head and neck (HN) cancer
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Ho, A. L.; Rao, S. S.; Shen, R.; Korte, S. H.; Lisa, D. M.; Ganly, I.; Katabi, N.; Patel, S. G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Ten years of progress in head and neck cancers
    Journal Article

    Baxi, S.; Fury, M.; Ganly, I.; Rao, S.; Pfister, D. G.
    Journal of the National Comprehensive Cancer Network (2012)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Journal Article

    Fury, M. G.; Sherman, E.; Lisa, D.; Agarwal, N.; Algazy, K.; Brockstein, B.; Langer, C.; Lim, D. ; Mehra, R.; Rajan, S. K.; more...
    Journal of the National Comprehensive Cancer Network (2012)

    Fulltext@MSK | Save